JP7761277B2 - 神経系血管バリアーの可逆的開口剤 - Google Patents

神経系血管バリアーの可逆的開口剤

Info

Publication number
JP7761277B2
JP7761277B2 JP2022543991A JP2022543991A JP7761277B2 JP 7761277 B2 JP7761277 B2 JP 7761277B2 JP 2022543991 A JP2022543991 A JP 2022543991A JP 2022543991 A JP2022543991 A JP 2022543991A JP 7761277 B2 JP7761277 B2 JP 7761277B2
Authority
JP
Japan
Prior art keywords
nervous system
cypa
barrier
therapeutic agents
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022543991A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022039223A1 (https=
Inventor
栄二 池田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamaguchi University NUC
Original Assignee
Yamaguchi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamaguchi University NUC filed Critical Yamaguchi University NUC
Publication of JPWO2022039223A1 publication Critical patent/JPWO2022039223A1/ja
Application granted granted Critical
Publication of JP7761277B2 publication Critical patent/JP7761277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022543991A 2020-08-21 2021-08-19 神経系血管バリアーの可逆的開口剤 Active JP7761277B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020139886 2020-08-21
JP2020139886 2020-08-21
PCT/JP2021/030373 WO2022039223A1 (ja) 2020-08-21 2021-08-19 神経系血管バリアーの可逆的開口剤

Publications (2)

Publication Number Publication Date
JPWO2022039223A1 JPWO2022039223A1 (https=) 2022-02-24
JP7761277B2 true JP7761277B2 (ja) 2025-10-28

Family

ID=80323509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022543991A Active JP7761277B2 (ja) 2020-08-21 2021-08-19 神経系血管バリアーの可逆的開口剤

Country Status (4)

Country Link
US (1) US20230302082A1 (https=)
EP (1) EP4201425A4 (https=)
JP (1) JP7761277B2 (https=)
WO (1) WO2022039223A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073232A1 (ja) 2015-10-29 2017-05-04 国立大学法人山口大学 神経系血管バリアー破綻抑制剤及び神経系疾患治療剤
JP2018502840A (ja) 2014-12-10 2018-02-01 ジェネンテック， インコーポレイテッド 血液脳関門受容体抗体及び使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006212721A1 (en) * 2005-02-10 2006-08-17 The University Of Western Australia Neuroprotective agents and methods of their use
EP1846107A1 (en) * 2005-02-10 2007-10-24 The University Of Western Australia Neuroprotective agents and methods of their use
WO2010146150A1 (en) * 2009-06-19 2010-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders
US20160220649A1 (en) * 2013-09-13 2016-08-04 Fundación Pública Andaluza Progreso Y Salud Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502840A (ja) 2014-12-10 2018-02-01 ジェネンテック， インコーポレイテッド 血液脳関門受容体抗体及び使用方法
WO2017073232A1 (ja) 2015-10-29 2017-05-04 国立大学法人山口大学 神経系血管バリアー破綻抑制剤及び神経系疾患治療剤

Also Published As

Publication number Publication date
US20230302082A1 (en) 2023-09-28
WO2022039223A1 (ja) 2022-02-24
JPWO2022039223A1 (https=) 2022-02-24
EP4201425A1 (en) 2023-06-28
EP4201425A4 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
JP4806258B2 (ja) 脳移行活性を有するポリペプチド、およびその利用
CN105431162B (zh) 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
JP2002512038A (ja) 被験体における腫瘍の浸潤または蔓延の阻害法
CN105263958A (zh) p97片段及其应用
JP2019535651A (ja) Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法
US20120231014A1 (en) Neural Regeneration
US20260001943A1 (en) Anti-elastin antibodies and methods of use
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
KR20220140543A (ko) Panx1 연관 질환의 치료
Wang et al. Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways
EP1481007B1 (en) Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
JP7761277B2 (ja) 神経系血管バリアーの可逆的開口剤
US8927498B2 (en) Compositions and methods useful in enhancement of memory
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
US11674959B2 (en) Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
JP2003530299A (ja) 標的化薬物送達のための方法および組成物
TW202003015A (zh) Ｃ端腦部多巴胺神經滋養因子（ｃｄｎｆ）及中腦星狀細胞－衍生之神經滋養因子（ｍａｎｆ）片段、包含彼之醫藥組成物及其用途
JP4988711B2 (ja) 神経再生ペプチド及びそれを含む処方物
Zhang et al. Expression of N-Terminal Cysteine Aβ42 and Conjugation to Generate Fluorescent and Biotinylated Aβ42
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
CN120098147B (zh) 一种纳米自组装抗Aβ抗体及其制备方法和应用
JP2025540675A (ja) オクタデカニューロペプチド（ｏｄｎ）およびその合成誘導体を含む組成物、ならびに食物摂取、肥満、体重、吐き気および嘔吐の調節のための使用方法
EP1387698B1 (en) Method of preventing cell death using antibodies to neural thread proteins
WO2026020125A1 (en) Chelation therapy to limit cell senescence

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251008

R150 Certificate of patent or registration of utility model

Ref document number: 7761277

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150